Abeona Therapeutics receives FDA Fast Track designation for its ABO-101 gene therapy

Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company co-headquartered in Cleveland and New York, has received a boost from federal regulators with respect to development of a therapy for a metabolic disorder.

The company announced in a news release on Thursday, April 4, that the U.S. Food and Drug Administration has granted Fast Track designation to ABO-101, which is Abeona’s one-time gene therapy for Sanfilippo syndrome type B, or MPS IIIB.

Click here to read the complete article.

Story excerpt provided by Crain’s Cleveland Business.

Originally published April 4, 2019.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: